cjc-1295 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-05. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
== Epidemiology == Obesity prevalence in Brazil has increased steadily over recent decades. Data from the Vigitel surveillance system indicate that the prevalence of obesity among adults increased from 11.8% in 2006 to 25.7% in 2024. During the same period, the prevalence of excess weight increased from 42.6% to 62.6%. The increase corresponds to a growth of approximately 118% in obesity prevalence over an eighteen-year period. No sustained decline was observed during the surveillance period. A systematic review and meta-analysis published in 2024 estimated the pooled prevalence of obesity among Brazilian adults at approximately 20%, with higher prevalence observed in the South and Southeast regions.
Chemical Garden at The Periodic Table of Videos (University of Nottingham) Chemical Gardens (Colloidal garden) at (http://chemistry-chemists.com) Chemobrionics (COST Action linking European research groups to stimulate innovative and high-impact interdisciplinary scientintific research on chemical gardens) Chemobrionics Database
Chief of the Defence Force – overall senior command officer Chief of the Army Chief of the Air Force Chief of the Navy Chief of the Medical Service (Surgeon General) Staff Divisions under the Chief of Defence Staff included:
== Other poisonous plants == Many other plants not commonly used in food or drink are also poisonous, and care should be taken to avoid accidentally contacting or ingesting them. Some of these are popular ornamental plants or are cultivated for purposes other than consumption.
Sources: en.wikipedia.org
== Regulation == Insofar as both IAPP and insulin are produced by the pancreatic β-cells, impaired β-cell function (due to lipotoxicity and glucotoxicity) will affect both insulin and IAPP production and release. Insulin and IAPP are regulated by similar factors since they share a common regulatory promoter motif. The IAPP promoter is also activated by stimuli which do not affect insulin, such as tumor necrosis factor alpha and fatty acids. One of the defining features of Type 2 diabetes is insulin resistance. This is a condition wherein the body is unable to utilize insulin effectively, resulting in increased insulin production; since proinsulin and proIAPP are cosecreted, this results in an increase in the production of proIAPP as well. Although little is known about IAPP regulation, its connection to insulin indicates that regulatory mechanisms that affect insulin also affect IAPP. Thus blood glucose levels play an important role in regulation of proIAPP synthesis.
=== Benzofurans === Benzofurans are similar in structure to MD(M)A but differ in that the methylenedioxy groups have been modified, removing one of the two oxygens in the methylenedioxy ring to render a benzofuran ring.
Dow AgroSciences – poultry vaccine against Newcastle disease virus (first PMP to be approved for marketing by the USDA Center for Veterinary Biologics Dow never intended to market the vaccine. "'Dow Agrosciences used the animal vaccine as an example to completely run through the process. A new platform needs to be approved, which can be difficult when authorities get in contact with it for the first time', explains the plant physiologist Stefan Schillberg, head of the Molecular Biology Division at the Fraunhofer Institute for Molecular Biology and Applied Ecology Aachen." Fraunhofer Institute for Molecular Biology and Applied Ecology, with sites in Germany, the US, and Chile is the lead institute of the Pharma Planta consortium of 33 partner organizations from 12 European countries and South Africa, funded by the European Commission. Pharma Planta is developing systems for plant production of proteins in greenhouses in the European regulatory framework. It is collaborating on biosimilars with Plantform and PharmaPraxis (see below). Genzyme – antithrombin III in goat milk GTC Biotherapeutics – ATryn (recombinant human antithrombin) in goat milk Icon Genetics produces therapeutics in transiently infected Nicotiana benthamiana (relative of tobacco) plants in greenhouses in Halle, Germany or in fields. First product is a vaccine for a cancer, non-Hodgkin's lymphoma. Iowa State University – immunogenic protein from E. coli bacteria in pollen-free corn as a potential vaccine against E.
Glycerol () is a sugar alcohol with chemical formula C3H5(OH)3. It has three carbon atoms with one hydroxyl group on each. Glycerol is a colorless, odorless, sweet-tasting, viscous liquid at Standard Ambient Temperature and Pressure (SATP). Because of its three hydroxyl groups, glycerol is miscible with water and is hygroscopic in nature. The glycerol backbone is found in lipids known as glycerides, where one or more of the hydroxyl groups are esterified with fatty acids. The most abundant of glycerides are triglycerides (found in animal fats and vegetable oils), the form in which glycerol is most commonly found in nature. It is also widely used as a sweetener in the food industry and as a humectant in pharmaceutical formulations. Modern use of the word glycerine (alternatively spelled glycerin) refers to commercial preparations of glycerol that are less than 100% pure, typically 95%.
== Trial == Norris, recorded as being of Egilsay Terrace, Glasgow, went to trial in 2007 at Newcastle Crown Court. Norris's father did not object to the decision to charge his son, whom he described as "scum". At trial Norris denied ever having predicted Hall's death, despite having admitted this in police interviews. He admitted giving Vera Wilby and Doris Ludlam overdoses of morphine on 17 May and 25 June 2002 respectively (police had found these injections recorded by him in the hospital records). He had given Ludlam twice the allowed dose of morphine. It was highlighted that, when police first interviewed him, Norris had not mentioned the cases of Ludlam, Bourke and Crookes when he was asked if he had ever had experience of patients falling into hypoglycaemic comas, even though that is what they had experienced when Norris was on duty. Police said they believed this was done on purpose so he didn't arouse suspicion about those cases at that stage, since they had not yet been uncovered by investigators. It was also brought to the jury's attention that documents had been found at Norris's home detailing a less painful way of injecting morphine. Norris claimed, despite the blood test evidence, that none of the patients had been injected and if they were then an 'intruder' must have done it (since records showed no other staff member could have been responsible). This is despite the fact that the insulin fridge, where the drug had apparently been taken from, had a coded access and only medical staff could access it.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.